Cancer News and Research

Latest Cancer News and Research

Cigarette smoking continues to cause nearly three in ten cancer deaths in the U.S.

A new American Cancer Society study finds that despite significant drops in smoking rates, cigarettes continue to cause about three in ten cancer deaths in the United States. The study, appearing in the Annals of Epidemiology, concludes that efforts to reduce smoking prevalence as rapidly as possible should be a top priority for the U.S. public health efforts to prevent cancer deaths.

10 Dec 2014

New guide documents threat endocrine-disrupting chemicals pose to human health

As governments, industry and public interest groups from across the globe prepare to meet next week to discuss endocrine-disrupting chemicals and other international chemical safety issues, the Endocrine Society and IPEN released a new guide documenting the threat endocrine-disrupting chemicals (EDCs) pose to human health.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

Advances in fight against TB, sudden cardiac death

Research projects into two of the biggest killers in worldwide health, tuberculosis and sudden cardiac death, will be the subjects of the University of Leicester Graduate School Doctoral Inaugural Lectures, delivered by two of the winners of this year's PhD prizes in the College of Medicine, Biological Sciences and Engineering.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).

10 Dec 2014

Molecular response criteria examined for CML

The limitations in determining molecular response in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitor therapy have been reviewed in Cancer.

9 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found.

9 Dec 2014

Simple blood test could help to detect breast cancer early

It may be possible to develop a simple blood test that, by detecting changes in the zinc in our bodies, could help to diagnose breast cancer early.

9 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

$Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors$

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors.

9 Dec 2014

Cannabis Science, CFA partner to improve health-related education infrastructure in Africa

Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa to help improve the healthcare and health-related education infrastructure in Africa.

9 Dec 2014

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.

9 Dec 2014

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively.

9 Dec 2014

Researchers freeze biological structures to illustrate DNA double-strand break process

Scientists from the Spanish National Cancer Research Centre, led by Guillermo Montoya, have developed a method for producing biological crystals that has allowed scientists to observe --for the first time-- DNA double chain breaks. They have also developed a computer simulation that makes this process, which lasts in the order of millionths of a second, visible to the human eye.

9 Dec 2014

Study finds that disarray in methylation helps tumors adapt to changing circumstances

The genetic tumult within cancerous tumors is more than matched by the disorder in one of the mechanisms for switching cells' genes on and off, scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.

9 Dec 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

9 Dec 2014

Opioid tramadol can increase hospitalization risk for hypoglycemia

The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report published online by JAMA Internal Medicine.

9 Dec 2014

Cancer News and Research

Latest Cancer News and Research

Cigarette smoking continues to cause nearly three in ten cancer deaths in the U.S.

New guide documents threat endocrine-disrupting chemicals pose to human health

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Advances in fight against TB, sudden cardiac death

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Molecular response criteria examined for CML

PD-1, PD-L1 differentially expressed in NSCLC

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

Simple blood test could help to detect breast cancer early

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Cannabis Science, CFA partner to improve health-related education infrastructure in Africa

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

Researchers freeze biological structures to illustrate DNA double-strand break process

Study finds that disarray in methylation helps tumors adapt to changing circumstances

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Agent THZ1 shrinks human-like small cell lung tumors in mice

Opioid tramadol can increase hospitalization risk for hypoglycemia

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Newsletters you may be interested in